Shattuck Labs Q2 FY26 net loss widens to $15.2 million; R&D expenses rise to $11.7 million
STTK•Clinical program updates
- Phase 1 data for lead DR3 blocker SL-325 showed 3.7% antidrug antibodies and TL1A-binding blockade to DR3 for over three months at ≥1 mg/kg doses.
- The RECEPTIVE-CD1 Phase 2b Crohn’s trial is expected to start in Q3 2026, with 12-week endoscopic response data expected in H1 2028.
Q2 FY26 financial results
- Shattuck posted a GAAP net loss of $15.2 million, widening from $12.5 million a year earlier, with loss per share improving to $0.12 from $0.24.
- GAAP R&D expense rose to $11.7 million from $8.7 million, while GAAP G&A expense edged up to $4.5 million from $4.4 million.
- Cash, cash equivalents and short-term investments climbed to $208.3 million from $50.5 million, with runway expected to extend into 2029.
